SCHEMBL6602248

SCHEMBL6602248

Brc1ccc2cc(OCCn3nc(-c4ccccc4)cc3OCCN3CCOCC3)ccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
FGFR1 P11362 1/20 0.47
SRC P12931 1/20 0.47
PTPN1 P18031 1/20 0.46
TSHR P16473 1/20 0.46
PPARG P37231 1/20 0.46
MAPK1 P28482 1/20 0.45
ADORA2A P29274 2/20 0.45
ADORA1 P30542 2/20 0.45
ADORA3 P0DMS8 1/20 0.45
ADORA2B P29275 1/20 0.45
LTA4H P09960 1/20 0.45
ACHE P22303 2/20 0.45
BCHE P06276 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6607212 0.83 MAPT (0.43) NPC1RAB9APPARGADORA2AADORA1
SCHEMBL6797974 0.82 RAB9A (0.41) NPC1RAB9APTPN1PPARGKDM4E
SCHEMBL5442329 0.81 TSHR (0.66) NPC1RAB9ATSHRMAPK1LTA4H
SCHEMBL6603315 0.80 TTK (0.35) NPC1RAB9ATSHRPPARGMEN1
SCHEMBL6602434 0.79 PPARG (0.39) NPC1RAB9APPARGKDM4EMEN1
SCHEMBL6603505 0.77 IKBKB (0.41) NPC1RAB9AMAPK1ALDH1A1MEN1
SCHEMBL11123142 0.75 NPC1 (0.54) NPC1RAB9AFGFR1SRCPTPN1
SCHEMBL29455968 0.75 TSHR (0.55) NPC1RAB9ATSHRLTA4HACHE
SCHEMBL22137628 0.75 TSHR (0.55) NPC1RAB9ATSHRLTA4HACHE
SCHEMBL4420934 0.74 NPC1 (0.65) NPC1RAB9ALTA4HKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 NPC1 2642/4885RAB9A 2533/4885FGFR1 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.